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Abstract
Eukaryotic cell surface glycolipids can act as both the primary interface between bacteria and their host and secondly as a
targeting mechanism for bacterial virulence factors. The former is characterized by redundancy in adhesin^receptor
interactions and the latter by a higher affinity, more restrictive glycolipid binding specificity for targeting. Interactions of
verotoxin with its glycolipid receptor globotriaosylceramide and Helicobacter pylori binding to a variety of different
glycolipids, which can be environmentally regulated, provide examples of these differing modes of glycolipid receptor
function. Verotoxins are involved in endothelial targeting in the microangiopathies of hemorrhagic colitis and hemolytic
uremic syndrome (HUS). The highly restricted binding specificity and crystal structure of the verotoxin B subunit have
allowed theoretical modeling of the Gb3 binding site of the verotoxin B subunit pentamer which provides an approach to
intervention. Studies of the role of glycolipid function in verotoxin-induced disease have concentrated on the distribution of
Gb3 and its ability to mediate the internalization of the toxin within the target cell. The distribution of Gb3 within the renal
glomerulus plays a central role in defining the age-related etiology of HUS following gastrointestinal infection with VT
producing Escherichia coli. H. pylori, on the other hand, instigates a less distinct but more complex disseminated gastric
inflammation. Studies on the role of glycolipid receptors in H. pylori infection have been bogged down in establishing the
importance of each binding specificity defined. In addition, the physiological condition of the organism within the various
binding assays has not been extensively considered, such that spurious non-physiological interactions may have been
elucidated. The identification and cloning of a Leb binding adhesin and the identification of cell surface hsp70 as a mediator
of sulfoglycolipid binding under stress conditions may now allow a more molecular approach to define the role of glycolipid
recognition in this infection. ß 1999 Elsevier Science B.V. All rights reserved.
Keywords: Receptor-mediated endocytosis; Cytokine; Glycolipid analogue; Apoptosis
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 376
2. Verotoxins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 376
2.1. Role of the glycolipid receptor in disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 377
2.2. Gb3 and HIV-induced HUS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 378
0925-4439 / 99 / $ ^ see front matter ß 1999 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 9 9 ) 0 0 0 6 2 - 9
* Fax: +1-416-813-5993; E-mail : cling@sickkids.on.ca
BBADIS 61867 14-9-99
Biochimica et Biophysica Acta 1455 (1999) 375^386
www.elsevier.com/locate/bba
3. Glycolipid receptor-based approaches to the therapy and prophylaxis of verotoxin-induced
disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 378
3.1. The problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 378
3.2. Gb3 binding site . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379
3.3. Strategy for therapeutic approaches . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380
4. Helicobacter pylori/glycolipid recognition and pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . 381
4.1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 381
4.2. Adhesins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 381
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 384
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 384
1. Introduction
My interest in the receptor function of the eukary-
otic membrane glycolipids was sparked by the con-
served and high level of expression of sulfoglycoli-
pids within the male germ cells of vertebrates and
our isolation of a sulfoglycolipid binding protein
from testicular germ cells [1] which was later shown
capable of inhibiting fertilization in vitro [2] and in
vivo [3]. While several hypotheses have been postu-
lated concerning the pivotal role of cell surface car-
bohydrates in fertilization, even the two most widely
accepted have been called into question by studies of
transgenic mice [4,5] in which the crucial glycosyl
transferase has been knocked out and yet fertility is
retained.
It is amazing to realize how little is known with
certainty, concerning gamete interaction as compared
with other systems of cell recognition. Pathogenic
bacterial cell-host attachment provides examples of
such systems in which eukaryotic cell surface glyco-
lipids play a major receptor role [6]. Indeed, some
bacteria implicated in infertility bind speci¢cally to
the sulfoglycolipids characteristic of mammalian
spermatozoa [7]. Thus the interaction of bacteria
with their host glycolipid receptors may have features
in common with sperm/egg binding.
2. Verotoxins
Verotoxins are a family of Escherichia coli derived
bipartite toxins of the A1B5 subunit format. Four
members are known VT1, VT2, VT2c and VT2e dif-
fering primarily in the B subunit [8]. The latter is the
pig edema disease toxin and not found in strains
which infect man. The toxins are structurally homol-
ogous but VT1 and members of the VT2 series are
not cross-neutralizable. VT2 is most often associated
with human disease.
Gastrointestinal infection with verotoxin produc-
ing E. coli (VTEC) strains (primarily serotype
0157:H7) is responsible for two signi¢cant patholo-
gies, hemorrhagic colitis (HC) and hemolytic uremic
syndrome (HUS) [9,10]. Both these diseases are mi-
croangiopathies of the gastrointestinal and renal glo-
merular blood vessels, respectively. Of the two, HUS
is the more signi¢cant disease, being the primary
cause of acute pediatric renal failure, and despite
aggressive interventional therapy, still shows a mor-
bidity of about 5%.
HC, and particularly HUS, show an age-related
incidence, the majority of HUS cases occurring in
children under three and in the elderly following gas-
trointestinal infection with VTEC [11]. HC is usually
a prodrome of HUS, likely a result of the closer
proximity of the GI blood vasculature to the site of
infection. The mechanism of translocation of the
toxin across the mucosal barrier is essentially un-
known since mucosal cells are toxin receptor negative
[12].
HUS is de¢ned by a triad of symptoms: thrombo-
cytopenia, hemolytic anemia and renal microangio-
pathy. The disease was ascribed to a variety of etio-
logical agents but the pioneering epidemiological
studies of Karmali et al. [13] ¢rst established a link
with gastrointestinal VTEC infection, which has been
subsequently con¢rmed worldwide.
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2.1. Role of the glycolipid receptor in disease
Verotoxins (VT1 is virtually identical to the Shiga
toxin from Shigella dysenteriae and therefore was
also called Shiga-like toxin or Stx) bind speci¢cally
to the galabiose terminal disaccharide moiety of glo-
botriaosyl ceramide-Gb3 (GalK1-4^GalL1-4 glucosyl
ceramide) [14^16]. The P1 glycolipid also terminating
in a galK1-4 gal disaccharide structure is also bound
in in vitro assays. The presence of Gb3 in the plasma
membrane is a prerequisite for cell sensitivity to ver-
otoxin-induced cytopathology in vitro and Gb3 neg-
ative cells can be sensitized to the action of verotoxin
by the incorporation of exogenous Gb3 [17]. How-
ever, other cellular processes are necessary for cyto-
pathology, including internalization and intracellular
tra⁄cking of the toxin receptor complex. Thus the
presence of Gb3 alone may not necessarily re£ect cell
selectivity or degree of cell sensitivity to VT [18].
Gb3 is expressed on human platelets and binds VT
[19] but VT has no e¡ect on platelet aggregation in
vitro [20] making it unlikely that thrombocytopenia
in HUS is directly VT-induced. Similarly, red blood
cells contain Gb3 but bind VT weakly and only at
4‡C [21], making it unlikely that VT binding is di-
rectly responsible for the hemolysis in HUS either.
Gb3 expression, however, likely plays a crucial role
in determining sensitivity to verotoxin-induced renal
disease. HUS is primarily a disease of the renal glo-
meruli and rarely occurs in adults except in the eld-
erly. Staining of frozen sections of human pediatric
kidney shows signi¢cant toxin binding to cells within
the renal glomeruli [22]. In addition, collecting ducts
and a subset of renal tubules are also stained. In the
adult, however, there is little or no staining by ver-
otoxin within the glomerulus. A subset of distal tu-
bules and collecting ducts is stained as in the pedia-
tric samples. Thus the age-related incidence of HUS
correlates with the expression of the toxin receptor,
Gb3, within the renal glomerulus, thus indicating
toxin receptor distribution plays a central role in
the induction of pathology. Studies in the pig model
of verocytotoxemia support such a conclusion, in
that site speci¢c mutagenesis of the VT2e toxin B
subunit to alter the glycolipid binding speci¢city
from Gb4+Gb3 to Gb3 alone, resulted in the induc-
tion of pathology in di¡erent tissues and this corre-
lated with the tissue Gb3 expression [23].
In the elderly, HUS again is prevalent following
gastrointestinal VTEC infection, yet the renal glo-
meruli of such patients are also receptor negative
[22]. The explanation for this ¢nding likely resides
in the regulation of Gb3 synthesis within this tissue.
Although renal glomerular endothelial cells from eld-
erly patients are receptor negative in situ, isolation of
such glomeruli and culture of the endothelial cells
within, results in the growth of endothelial cells
which have an extremely high Gb3 content and are
highly sensitive to VT-induced cytopathology in vi-
tro. [24]. Thus, endothelial cells in situ can be in-
duced to synthesize Gb3 by appropriate stimuli, eg.,
growth. Similar stimulation of cultured endothelial
cell Gb3 synthesis occurs after treatment with certain
cytokines eg. TNF, IL1L or LPS [25^28]. We pro-
pose, therefore, that the etiology of HUS in the eld-
erly may be the result of an inappropriate response,
as the immune system ages, to circulating LPS from
the gastrointestinal infection (or LPS-induced cyto-
kines) to stimulate renal endothelial cell Gb3 synthe-
sis which sensitizes cells for subsequent verotoxin-in-
duced injury. Thus Gb3 expression plays a central
role in determining the age-related incidence of
VTEC-induced HUS.
While the presence of renal glomerular Gb3 may
be a primary risk factor for the development of HUS
following gastrointestinal VTEC infection, the regu-
lation of Gb3 synthesis within the target tissue may
be complex. Macrophages and monocytes contain
Gb3 but are insensitive to the cytopathology of ver-
otoxin. Treatment of such cells with VT in vitro re-
sults in the increased synthesis of interleukin-1L and
tumor necrosis factor, and these are the very cyto-
kines which have been shown to induce Gb3 synthe-
sis in cultured endothelial cells. [29^31]. Thus, the
etiology of HUS may contain an ampli¢cation com-
ponent in which verotoxin itself stimulates the pro-
duction of cytokines by monocytes which render en-
dothelial cells sensitive to the toxin. Such a scenario
might relate to the several days time interval between
the onset, and even resolution, of gastrointestinal
microvasculopathy as compared with the onset of
renal sequelae.
Furthermore, the isoform of Gb3 synthesized may
be highly relevant to determining VT sensitivity. In
early studies we showed the importance of the lipid
moiety of Gb3 in VT binding [32,33] and reported
BBADIS 61867 14-9-99
C.A. Lingwood / Biochimica et Biophysica Acta 1455 (1999) 375^386 377
that increasing the fatty acid chain length of Gb3
increases VT 1 binding, to a C22 limit when further
extension becomes inhibitory [34]. In our studies of
astrocytoma and ovarian carcinoma cell lines we
found di¡ering sensitivities to VT1 despite compara-
ble Gb3 concentrations. We have found that cells of
higher sensitivity tend to synthesize Gb3 with shorter
fatty acid chains (C:16 and C:18) and that the VT^
receptor complex is internalized to compartments
consistent with the ER, nuclear envelope and nu-
cleus, whereas cells of reduced VT sensitivity synthe-
size Gb3 with longer chain fatty acids (C:22 and
C:24) and target the receptor complex to organelles
consistent with Golgi/endosomes [35]. Thus, intracel-
lular tra⁄c of the toxin^receptor complex may play a
role in determining sensitivities to cytopathology and
such an intracellular routing may be regulated by the
fatty acid isoform of the Gb3. Apparently VT bind-
ing and intracellular tra⁄cking show opposing trends
in terms of Gb3 fatty acid chain length. It is likely
that cell surface VT binding is excess to that required
for killing and that the routing plays the more sig-
ni¢cant role in determining cell sensitivity. Epidemio-
logical studies have identi¢ed red cell Gb3 fatty acid
content as a risk factor for the development of pe-
diatric HUS following VT exposure [36]. The lack of
VT binding to red cells suggests that the red cell
glycolipid fatty acid phenotype serves as a marker
of the fatty acid content of cells more germane to
the disease, e.g., renal endothelial cells, mesangial
cells etc.
Recently primary human renal tubular epithelial
cells have been shown to be highly susceptible to
VT1 in vitro [37]. This correlates with the detection
of some tubular damage early in VTEC-induced
HUS. However, the overall Gb3 level did not corre-
late with increased VT1 cytotoxicity observed follow-
ing cytokine treatment of such cells, suggesting that
Gb3 isoform and intracellular VT1 tra⁄cking may
play a role in modulating epithelial cell VT1 sensitiv-
ity.
2.2. Gb3 and HIV-induced HUS
It is also of interest to note that pediatric AIDS
patients have a high incidence of an atypical HUS
[38]. Transgenic mouse models of HIV infection have
been constructed and one of these shows the sponta-
neous generation of a nephropathy as a function of
age, which is similar to the HUS observed in HIV-
infected patients [39]. We have recently found that
the renal Gb3 content of the HIV1 transgenic mouse
is markedly elevated compared with wild-type litter
mates [40]. Overlay of frozen sections of the mouse
transgenic HIV kidney showed increased binding of
FITC labeled VT1 and anti Gb3 to renal tubular
cells, suggesting that Gb3 was elevated in these cells.
The results suggest that virus-induced elevation of
renal Gb3 might cause renal nephropathy and may
also sensitize HIV patients to VTEC infections.
3. Glycolipid receptor-based approaches to the
therapy and prophylaxis of verotoxin-induced
disease
3.1. The problem
Since the receptor glycolipid globotriaosylceramide
plays such an important role in determining toxin
mediated tissue damage, our laboratory has taken
the approach of attempting to generate soluble re-
ceptor analogues which can bind the toxin and may
thereby prevent systemic targeting of Gb3 containing
tissues. This has proved to be a di⁄cult problem and
has turned out to have far wider implications in
terms of the presentation of membrane glycolipid
carbohydrate for ligand binding in general.
While many ligands, particularly of prokaryotic
origin, bind glycolipid carbohydrate [6,41] most of
the examples studied in detail demonstrate that the
carbohydrate sequence is the only determinant of
binding speci¢city. For example, although E. coli
bearing PapG adhesins bind to globo series glycoli-
pids [42] this binding is e¡ectively inhibited by the
galabiose disaccharide, and the same holds for Strep-
tococcus suis binding to globo series glycolipids [43].
For both these systems, galabiose derivatives can be
used to precisely de¢ne the binding epitopes within
the saccharide moiety [44,45].
Unfortunately, the situation is quite di¡erent for
verotoxin recognition of these same glycolipids.
While the toxin binding speci¢city resides exclusively
within the carbohydrate moiety of the glycolipid [46],
the binding of verotoxin to galabiose containing gly-
colipids is markedly a¡ected by the lipid moiety
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[32,34] such that the binding can be completely ab-
lated if an inappropriate species is conjugated [33].
Similarly the binding to the free oligosaccharide [47]
is at least ¢ve orders of magnitude reduced compared
to Gb3 within a model membrane [48].
3.2. Gb3 binding site
Our molecular modeling studies, combined with
binding to galabiosyl glycolipid deoxy analogues
have identi¢ed two potential Gb3 binding sites per
B subunit monomer [46,49,50] (Fig. 1). Binding with-
in site 1, essentially a cleft between adjacent B sub-
unit monomers, is consistent with site speci¢c muta-
genesis studies thus far reported and was used in
homology modeling to explain the additional binding
of VT2e to Gb4 and why all members of the vero-
toxin family preferentially bind aminoGb4 [46]. The
second site, a depression in the B subunit surface
which opposes the host cell plasma membrane, was
postulated to be more important in the binding of
VT2c and might possibly explain the di¡erent spec-
trum of pathology in animal models observed for
this toxin [48]. The second site accommodated a dif-
ferent Gb3 carbohydrate conformer in respect to the
relative orientation of the glycosidic linkage to the
ceramide [46]. Previous theoretical studies [51] had
indicated that the relative conformation of the car-
bohydrate with respect to the plasma membrane was
in fact determined by the relative plane of the plasma
membrane in relationship to the head group of the
glycolipid. This relationship will be determined by
the lipid composition of the plasma membrane and
the lipid composition of the glycolipid. Thus fatty
acid heterogeneity may well in£uence the relative
plane of the plasma membrane in respect to the gly-
colipid head group and thereby alter the distribution
of conformations. Such an e¡ect would then explain
the di¡erential binding of VT1 and VT2c to di¡erent
Gb3 fatty acid isoforms [34]. Potentially di¡erent
fatty acid isoforms might preferentially dock into
each of the two distinct Gb3 binding sites within
the B subunit.
The verotoxin 1B subunit pentamer has now been
cocrystallized with the Gb3 oligosaccharide linked to
a C8 hydrocarbon chain [52]. This study identi¢ed
three Gb3 binding sites per monomer, one corre-
sponding to the cleft site, one to the second site,
similar to that de¢ned by modeling, and a third cor-
responding to the region of tryptophan 34 (see Fig.
1). Site speci¢c mutagenesis, however, suggests that
this third site plays a minor role in VT cytotoxicity.
The orientation of the Gb3 sugar in site I is similar to
that predicted except that the interactions involving
the terminal K-galactose are di¡erent, such that the
sugar is more perpendicular to the cell surface and
does not interact with residues from the adjacent
subunit (this orientation does not explain the binding
Fig. 1. Location of the putative Gb3 binding site in the VT B subunit. Two of the ¢ve B subunit monomers are shown. The view is
from the side ^ the surface opposing the cell membrane is at the bottom and the A subunit would be at the top. The position of
Phe30, which plays a crucial role in binding [1], is shown. Gb3 binding sites I and II are essentially on either side of Phe30. The posi-
tion of Trp34 at the base of the K helix which forms the central pore of the B subunit pentamer is also indicated.
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of amino Gb4). The Gb3 sugar in site II, however, is
oriented in a di¡erent direction from that predicted.
The solution structure of the VT1 B subunit pentam-
er complexed with the Gb3 oligosaccharide has also
been recently solved by NMR [53]. These studies
con¢rmed the primary occupancy of site II as ob-
served in the cocrystal. The authors estimate a max-
imum occupancy of 15% for site I, but saw no evi-
dence for association of the sugar with tryp 34.
These data do not necessarily, however, indicate
that the modeling predictions are wrong. As indi-
cated above, the lipid-free Gb3 sugar is many orders
of magnitude less e¡ectively bound by VT1. While
multivalency, such as may occur for the intact Gb3,
will increase binding a⁄nity to the B subunit pen-
tamer, the cocrystal studies conclude there is no evi-
dence of cooperativity between binding sites [52]. We
propose the lipid moiety plays a crucial role in the
‘presentation’ of the Gb3 oligosaccharide for binding
and the structure of the complex with the free sugar
may be of limited relevance to VT^membrane glyco-
lipid recognition. Studies using £uorescence reso-
nance energy transfer (FRET) on the binding of
the VTB subunit to liposomes containing a coumarin
derivative of Gb3 have allowed the measurement of
the distance between the £uor of the bound receptor
and tryp34 [54]. This distance is consistent with the
occupancy of site II as modeled [46] but not with the
occupancy of any site as de¢ned by the oligosacchar-
ide^VTB complex.
In order to generate potential high a⁄nity inhib-
itors of VT/Gb3 binding, the role of the lipid moiety
in binding must be of primary consideration. Struc-
tures which can be docked into site I as we have
de¢ned it, rather than into the sites inferred from
the VT/oligosaccharide cocrystals, have the greatest
likelihood of e⁄cacy as inhibitors of VT binding to
Gb3 on target cells in vivo.
It is also possible that ‘site-selective’ inhibitors
could be made. The FRET experiments are consis-
tent with site II occupancy rather than site I [54]. On
measurement of receptor activity by TLC overlay,
the coumarin-Gb3 was found to bind preferentially,
in comparison to Gb3, to VT2c rather than VT1,
suggesting that the coumarin-Gb3 may be a Gb3 de-
rivative which binds preferentially to site II (which
we have postulated is preferentially used by VT2c
[46]). Thus by modifying the lipid moiety to incorpo-
rate a coumarin group, a site II-speci¢c Gb3 deriva-
tive may have been generated.
3.3. Strategy for therapeutic approaches
We have therefore begun a systematic study to
determine the in£uence of the lipid moiety on glyco-
lipid receptor function in order to generate water
soluble mimics of membrane glycolipid receptors.
We have used two separate approaches.
3.3.1. Generation of galabiosyl dimers
In collaboration with Dr. G. Magnusson, Univer-
sity of Lund, we have examined the ability of a large
variety of galabiosyl dimers linked by various spacer
groups to inhibit the binding of VT1 to Gb3 in a
receptor ELISA. For the most part these compounds
have proven inactive. At the moment, no rationale
for the distinction between active and inactive gala-
biose dimers can be discerned. The active dimers are
not su⁄cient to cross-link sites on adjacent B sub-
units but may be su⁄cient to cross-link site I and site
II. Minor changes in the nature of the chemical
cross-linker make a major di¡erence in the ability
to inhibit toxin binding. However, the ¢nding that
some monomeric species also inhibit, suggests the
possibility that the second galabiose may act as the
‘aglycone’ to properly orient the ¢rst galabiose. Tri-
meric and tetrameric species were not active.
3.3.2. Soluble glycolipid mimics
The second approach is to try to generate soluble
glycolipid derivatives which mimic the e¡ect of the
lipid moiety and membrane presentation as determi-
nants of the carbohydrate receptor function. To this
end we have developed a new procedure for the
quantitative cleavage of the sphingosine double
bond to generate the ‘glycoceramidic acid’. The pro-
cedure involves the catalytic oxidation of the double-
bond with potassium permanganate in an oxidation-
resistant solvent together with a system for regener-
ating permanganate from manganese dioxide gener-
ated during the oxidation reaction. These two addi-
tional components prevent the generation of side
reactions and precipitants which remove product.
We have been able to obtain yields on the order of
90% of a single product corresponding to the cerami-
dic acid of any given glycolipid [55]. The availability
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of this oxidation procedure opens up a new vista for
the generation of new bioactive glycolipid deriva-
tives, including the generation of novel soluble Gb3
derivatives which can compete for membrane bound
verotoxin Gb3 binding [56]. Such compounds may
open up a new approach to the prophylaxis of
HUS following gastrointestinal VTEC infection.
Clinical trials using a Gb3 oligosaccharide immo-
bilized on diatomaceous earth and given orally have
not proven particularly e¡ective in reducing HUS
following gastrointestinal VTEC infection [57]. The
availability of soluble receptor analogues capable of
competing for systemic toxin binding may well prove
a more e¡ective means of preventing the targeting of
GI-derived verotoxin to distal Gb3-containing tissue
sites in susceptible hosts. The availability of an in-
soluble receptor analogue within the GI tract itself
may be of limited protective bene¢t since the role of
free toxin within the gastrointestinal lumen in the
development of disease is unknown [12]. Toxin trans-
location across the GI tract is not mediated via a
receptor dependent process and it may be, for the
most part, associated with the direct attachment of
the VTEC organism to the mucosal cells, at the site
of closest apposition of eukaryotic and prokaryotic
membranes. If such a scenario proves to be the case,
an insoluble toxin receptor analogue may not have
access to toxin prior to translocation into the host.
Identi¢cation of patients at the hemorrhagic colitis
stage and systemic administration of a soluble recep-
tor analogue might well prevent the renal endothelial
cell toxin targeting which subsequently may develop
into HUS.
4. Helicobacter pylori/glycolipid recognition and
pathogenesis
4.1. Introduction
Helicobacter pylori has gone from being a subject
of medical incredulity and ridicule to an acknowl-
edged infection in half the population of the world.
Histological localization studies provide the most de-
¢nitive evidence for a speci¢c receptor for the attach-
ment of this organism to host cells. In gastric biop-
sies H. pylori can be seen associated with the mucus
and with the surface of mucosal cells within the an-
trum but no association with duodenal cells or with
duodenal metaplasia within the antrum is seen.
4.2. Adhesins
Several receptor^ligand interactions have been im-
plicated in the mechanism of H. pylori host cell at-
tachment and, for the most part, these involve sur-
face carbohydrates of the host cell and in turn, these
are for the most part, concerned with glycolipid rec-
ognition [58]. The ¢rst adhesin/receptor system impli-
cated in H. pylori adhesion was the recognition of
sialic acid [59]. Such sialyl residues were expressed
both on glycoproteins and GM3 ganglioside. The
protein responsible for this sialic acid binding specif-
icity was subsequently cloned [60] but was found to
be a lipoprotein within the cell and not a surface
exposed adhesin [61]. Interestingly, multimeric 3P
sialyl lactose has been shown to inhibit H. pylori
binding to several cell lines in vitro and proposed
as a possible clinical therapeutic [62]. Sialated poly-
glycosyl ceramides have also been shown to bind H.
pylori [63] but this is independent of the putative
sialo adhesin mentioned above. The same group
has shown binding to a subpopulation of lactosyl
ceramide species containing hydroxy sphingosine
and hydroxylated fatty acids [64]. Binding of H. py-
lori to the Lewis b blood group structures (expressed
on both glycolipids and glycoproteins) has also been
reported [65], particularly for organisms of Helico-
bacter strains termed type 1, in which the vacuolat-
ing toxin is expressed. Type 1 H. pylori strains are
more frequently isolated from symptomatic patients,
whereas the type 2 strain are isolated most frequently
from patients without gastric symptoms. The adhesin
responsible for this Lewis b recognition has recently
been identi¢ed by a receptor crosslinking procedure
[66] and the gene identi¢ed from the genome se-
quence. Since this protein is more frequently ex-
pressed in the more pathogenic strains, it provides
a new focus for the prevention of clinical disease.
In particular, it will be of interest to determine
what host cell signal transduction pathways are dis-
turbed following cell surface Leb binding. The role of
Leb binding in clinical infections is contentious.
Although the incidence of ulcers is related to blood
group status [67], the colonization with H. pylori is
not [68]. Several groups have reported the lack of
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any role for these oligosaccharides in host cell attach-
ment [69,70], although the subsequent in£ammatory
response may be related to Lewis status [70]. Thus it
is possible that the recognition of Lewis b plays a
role in pathogenesis but not necessarily initial eu-
karyotic cell attachment [71]. However, a transgenic
mouse model in which the Le fucosyl transferase is
expressed in gastric mucosal cells has been developed
[72]. In this model, Leb plays a crucial role in H.
pylori mucosal attachment, which in turn is a re-
quirement for the development of gastritis. Only clin-
ical strains expressing the Leb adhesin were found
bound to the mouse gastric mucosal cells after chal-
lenge and only such mucosa showed gastritis [73].
Gastric in£ammation correlated with the presence
of anti Lex antibodies, suggesting the initiation of
an autoimmune reaction by the closely attached or-
ganisms, which themselves bear Lex oligosaccharides
within their LPS [74]. However in man, no relation-
ship between H. pylori and host Lewis status has
been found [75].
H. pylori is a hemagglutinin and several receptor
species were proposed based on the ability to agglu-
tinate erythrocytes of di¡erent species [76,77]. Our
original receptor binding speci¢cities were carried
out on the extracts of human erythrocytes and we
found that phosphatidyl ethanolamine was the major
species within the lipid extract bound [78,79]. No
di¡erence between red cells of di¡erent blood group
status was found. In comparison to PE binding, no
recognition of Lewis blood group glycolipids were
seen. These binding studies were carried out under
microaerophilic conditions but at neutral pH. Gan-
gliotriaosyl ceramide and gangliotetraosyl ceramide,
in addition to phosphatidyl ethanolamine, were
bound but these species were not detected in red cells
or Hep2 cells to which H. pylori had been shown to
bind. Ganglio series glycolipid are also poorly repre-
sented in the lipid extract of the human gastric mu-
cosa [80]. PE expression correlated with the eukary-
otic cell binding of H. pylori in vitro [81,82].
Although many cells express surface PE, the majority
of PE is normally found on the inner lea£et of the
plasma membrane bilayer. However, on induction of
apoptosis, one of the earliest markers is the loss of
the plasma membrane phospholipid asymmetry. This
has resulted in the use of annexin 5 which binds to
phosphatidyl serine being routinely used as a marker
of apoptotic cells. However, in addition to the in-
creased exposure of phosphatidyl serine, exposure
of phosphatidyl ethanolamine has been shown to
be increased following induction of apoptosis [83]
as we had predicted [84]. Interestingly, infection
with H. pylori has been found to increase the (nor-
mally low) percentage of apoptotic cells within the
gastric mucosa [85] allowing the speculation that
Helicobacter binding to gastric mucosal cells results
in the induction of apoptosis in those cells and this
then facilitates the binding of more H. pylori organ-
isms to the cells.
4.2.1. Assay conditions for receptor binding
H. pylori is a microaerophilic organism. In order
to determine the clinically relevant binding speci¢city
of this organism, it appears appropriate to determine
the binding speci¢city under microaerophilic condi-
tions, when the organism remains alive, as opposed
to conditions of normal oxygen tension when the
organism is dead. Most binding studies thus far re-
ported, however, have not been carried out under
such conditions. In addition, the organism’s primary
niche is highly acidic by nature and therefore, for
binding studies to meaningfully re£ect the in vivo
situation, they must be resistant to conditions of
pH 2. This condition has also not been tested in
any of the receptor binding studies described above.
It should be noted, however, that in the case of
Leb recognition, where such considerations were
breached in the most excessive manner [65], that, at
least for the transgenic mouse model, binding to Leb
oligosaccharide is the primary determinant for host
gastric tissue binding [73].
4.2.2. Stress response induces a change in
carbohydrate binding speci¢city
As mentioned above, H. pylori shows many di¡er-
ent adhesin^receptor interactions and it is likely that
binding to host tissue is a multi-faceted process.
However, we were particularly intrigued by reports
of H. pylori binding to sulfatides by tlc overlay, since
under our conditions, we were not able to show sul-
fatide binding by these organisms. In separate stud-
ies, we were investigating the interaction between an
hsp70 expressed on the surface of male germ cells
and sulfatide [86]. In light of the acidic nature of
the site of colonization of this organism, we investi-
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gated whether acid induced a stress response in H.
pylori to result in the surface expression of an hsp70
which could then mediate sulfatide recognition. This
hypothesis turned out to be the case and we were
able to show that brief incubation of H. pylori at
pH 2.5 resulted in an alteration in the glycolipid
binding speci¢city of this organism to include sulfa-
tides, and that this binding speci¢city could be pre-
vented by inclusion of inhibitors of protein synthesis
or by treating the bacteria with anti-hsp70 antibodies
[87]. A similar, though not so marked, change in
binding speci¢city to include sulfatide was seen fol-
lowing brief heat shock of the H. pylori organisms,
again indicating that the sulfatide recognition was
the result of a stress response in H. pylori. We
have subsequently cloned the hsp70 from H. pylori
and shown it to be preferentially upregulated by pH
rather than heat-induced stress [88]. Thus a binary
receptor model is proposed (Fig. 2) in which initial
colonization of the acid stomach resulted in the ex-
pression of heat-shock proteins on the cell surface of
this organism which bound to sulfated glycolipids
contained within the mucous layer. This binding
then prevents removal of the organism by the shear
forces of gastric peristalsis. Thus the high motility
and spiral structure of the organism, together per-
haps with the fact that the sulfated glycolipids are
not covalently incorporated into the mucus, allows
penetration of the mucous layer and access to the
gastric epithelium where the pH approaches neutral-
ity, and binding could then occur by an alternative
interaction possibly involving PE recognition.
This model is the ¢rst example of environmental
regulation of carbohydrate speci¢city and illustrates
Fig. 2. Binary receptor model for H. pylori attachment. Initial antral colonization occurs at acid pH which induces a stress response
in H. pylori to expose surface hsps to mediate sulfatide binding. Sulfatide (and other sulfate galactolipids) is contained within the mu-
cous layer. Sulfatide binding can thus mediate mucus attachment to prevent removal of H. pylori with the stomach contents. Sulfatide,
however, is not covalently attached to the mucus, so binding may still allow active penetration of the mucous layer, down a pH gra-
dient to the mucosal surface for attachment to the epithelial cells at approaching neutral pH.
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the importance of carrying out microbial receptor
binding assays under physiological conditions. Our
¢nding that fresh clinical isolates do not bind sulfa-
tide but that after prolonged in vitro culture, sulfa-
tide binding can be detected, suggests that organisms
in culture undergo a stress response as a result of
suboptimal conditions [88] and raises the important
question of the validity of studying strains continu-
ously maintained in culture. In terms of clinical path-
ology, it is noteworthy that the inhibitory activity of
oligosaccharide analogues to prevent H. pylori cell
attachment varied markedly between fresh and main-
tained strains, and the strain for which the genome
has been sequenced [89] was not representative of the
overall response [62].
The expression of cell surface heat shock proteins
to mediate sulfatide recognition is a theme that is
repeated often in both prokaryotic and eukaryotic
cell attachment. Mycoplasma attachment to sulfatide
in vitro is inhibited with anti-hsp70 antibodies. Sul-
fatide binding is induced in Haemophilus in£uenzae
following heat shock and this binding is inhibited in
the presence of anti-hsp70 [90] and hsp70s are ex-
pressed on the surface of Chlamydia trachomatis
[91]. In eukaryotic systems hsp70 is expressed on
the surface of male germ cells to mediate sulfatide
binding [92] and an hsp analogue is also expressed on
the surface of sea urchin eggs [93] which may serve a
similar function.
Since glycolipids are key components in the patho-
genesis of both verotoxin and H. pylori, the genera-
tion of soluble glycolipid derivatives which can
mimic the receptor activity of membrane glycolipids
is a potential avenue for the generation of new ap-
proaches to the prevention of bacterial disease.
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